➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Harvard Business School
McKinsey
Johnson and Johnson
McKesson

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,492,416

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,492,416
Title:2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR00001## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s): Kenda; Beno t (Emines, BE), Pasau; Patrick (Chastre, BE), Lallemand; Benedicte (Namur, BE)
Assignee: UCB Pharma, S.A. (Brussels, BE)
Application Number:13/222,477
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,492,416
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,492,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-004 May 12, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,492,416

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004297.8Feb 23, 2000

International Family Members for US Patent 8,492,416

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 282592   Start Trial
Austria 304999   Start Trial
Austria 325093   Start Trial
Austria 445597   Start Trial
Austria 488500   Start Trial
Australia 2001252144   Start Trial
Australia 2005200717   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.